The neoplasms of the anus discussed in this article are uncommon, and therefore lack a consistent diagnostic and treatment algorithm derived from prospective clinical trial datasets. There may be an opportunity to design prospective Phase II clinical trials, with established uniform surgical pathology, surgical technique guidelines, and endpoints. The American College of Surgeons Oncology Group may have an opportunity to design and carry out controlled clinical trials for select rare anal neoplasms. Such an effort may yield modern benchmarks with which to base subsequent patient care algorithms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.soc.2003.12.002 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!